Repurposing simeprevir uncovers a druggable KPNB1-p65-BCL2 survival axis in cancer
Cell Chemical Biology · 2026-07
DOI: 10.1016/j.chembiol.2026.07.005 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell Chemical Biology, 2026-07. Verfasst von Cong Li und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary and Critical Care Medicine, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, C…. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins c-bcl-2, Antineoplastic Agents, Transcription Factor RelA, Neoplasms. Die Arbeit nennt 46 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Proper subcellular protein localization is fundamental for protein function, yet cancer cells often exploit this machinery for survival. While the nuclear import receptor KPNB1 (importin β1) is overexpressed in various cancers, its oncogenic mechanisms remain incompletely understood and its therapeutic targeting remains in infancy. Through screening of an FDA-approved compound library, we uncovered simeprevir (Sim) and lusutrombopag (Lus) as direct KPNB1 inhibitors that disrupt its import complex assembly. These compounds blocked KPNB1-mediated nuclear import of p65, thereby suppressing Bcl-2 transcription and activating mitochondrial apoptosis. Overexpression of KPNB1, p65, or Bcl-2, but not nuclear localization signal (NLS)-deleted p65, reversed the effect of Sim/Lus. Sim induced apoptosis in multiple cancer cell lines by downregulating Bcl-2 expression and suppressed A549 xenografts growth without observable toxicity. Analysis of The Cancer Genome Atlas (TCGA) datasets substantiated the clinical relevance of the KPNB1-p65-Bcl-2 axis. Our study elucidates a therapeutically targetable KPNB1-p65-Bcl-2 survival axis in multiple cancers and establishes a foundation for developing next-generation KPNB1 inhibitors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pulmonary and Critical Care Medicine, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, Sichuan 610072, China; Department of Pathology, State Key Labo…
- Department of Pulmonary and Critical Care Medicine, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, Sichuan 610072, China.
- Department of Oncology, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning 116011, China.
- Department of Pathology, State Key Laboratory of Biotherapy and Cancer Centre, West China Hospital, Sichuan University, Collaborative Innovation Centre of Biotherapy, Chengdu, Sichuan 610041, China.
- Department of Pharmacy/Personalized Drug Therapy Key Laboratory of Sichuan Province, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, Sichuan 610072, China.
- Department of Pulmonary and Critical Care Medicine, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, Sichuan 610072, China. Electronic address: sunqingxiang@med.ue…
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Li, C., Yan, Q., Saeed, M. M., Luo, Y., Jiang, P., & Sun, Q. (2026). Repurposing simeprevir uncovers a druggable KPNB1-p65-BCL2 survival axis in cancer. Cell Chemical Biology. https://doi.org/10.1016/j.chembiol.2026.07.005
Vancouver
Li C, Yan Q, Saeed MM, Luo Y, Jiang P, Sun Q. Repurposing simeprevir uncovers a druggable KPNB1-p65-BCL2 survival axis in cancer. Cell Chemical Biology. 2026. doi:10.1016/j.chembiol.2026.07.005
BibTeX
@article{Li2026,
author = {Li, Cong and Yan, Qiaohua and Saeed, Muhammad Muddasar and Luo, Yubin and Jiang, Peidu and Sun, Qingxiang},
title = {Repurposing simeprevir uncovers a druggable KPNB1-p65-BCL2 survival axis in cancer},
journal = {Cell Chemical Biology},
year = {2026},
doi = {10.1016/j.chembiol.2026.07.005}
}
EUVIMED